Device Significantly Reduces Volume of Dye Needed for CA or PCI Interventions
By MedImaging International staff writers Posted on 01 Jun 2016 |
Image: The AVERT contrast modulation system (Photo courtesy of Osprey Medical).
The results of a large, late-breaking, clinical trial have demonstrated a new device that can significantly reduce the volume of radiographic dye required for patients who undergo a coronary angiography, or Percutaneous Coronary Intervention (PCI), but who are at risk of developing acute kidney injury (AKI).
The device was not able to reduce the sudden deterioration in renal function, called Contrast-Induced AKI (CI-AKI), which can occur following the administration of radiographic dye or Contrast Media Volume (CMV) during interventional cardiac procedures. CI-AKI affects around 20 – 30% of patients, especially those with previous renal impairment, or diabetes, and can cause increased morbidity and mortality.
The results of the study were presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions (Orlando, FL, USA). The operator of the AVERT device can control how much dye is injected in the coronary artery, and can dispose of the remaining dye into a reservoir. The prospective, randomized multi-center study took place at 39 sites, and included 578 patients who needed to undergo a coronary angiography and/or PCI, but who were at risk of CI-AKI.
The use of the AVERT device resulted in a relative reduction of 15.5% in CMV in all patients and a relative reduction of 22.8% in CMV for PCI patients. The researchers found no significant differences in CI-AKI, or adverse event rates, in both groups.
Roxana Mehran, MD, FSCAI, lead author of the study, from the Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital (SMMS; New York, NK, USA), said, “Physicians are extremely careful about the volume of dye they administer to patients; the greater the volume, the more problems a physician can encounter. The bottom line is the AVERT system is safe, easy to use and reduces contrast media volume without sacrificing image quality. While the use of this device did not result in a significant reduction of CI-AKI, there was one exception. A post-hoc analysis showed that in certain groups — patients with a GFR between 40-60 — CI-AKI was significantly reduced. The next step would be to study patients with moderate chronic kidney disease in a prospective randomized trial.”
Related Links:
Society for Cardiovascular Angiography and Interventions
Icahn School of Medicine at Mount Sinai Hospital
The device was not able to reduce the sudden deterioration in renal function, called Contrast-Induced AKI (CI-AKI), which can occur following the administration of radiographic dye or Contrast Media Volume (CMV) during interventional cardiac procedures. CI-AKI affects around 20 – 30% of patients, especially those with previous renal impairment, or diabetes, and can cause increased morbidity and mortality.
The results of the study were presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions (Orlando, FL, USA). The operator of the AVERT device can control how much dye is injected in the coronary artery, and can dispose of the remaining dye into a reservoir. The prospective, randomized multi-center study took place at 39 sites, and included 578 patients who needed to undergo a coronary angiography and/or PCI, but who were at risk of CI-AKI.
The use of the AVERT device resulted in a relative reduction of 15.5% in CMV in all patients and a relative reduction of 22.8% in CMV for PCI patients. The researchers found no significant differences in CI-AKI, or adverse event rates, in both groups.
Roxana Mehran, MD, FSCAI, lead author of the study, from the Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital (SMMS; New York, NK, USA), said, “Physicians are extremely careful about the volume of dye they administer to patients; the greater the volume, the more problems a physician can encounter. The bottom line is the AVERT system is safe, easy to use and reduces contrast media volume without sacrificing image quality. While the use of this device did not result in a significant reduction of CI-AKI, there was one exception. A post-hoc analysis showed that in certain groups — patients with a GFR between 40-60 — CI-AKI was significantly reduced. The next step would be to study patients with moderate chronic kidney disease in a prospective randomized trial.”
Related Links:
Society for Cardiovascular Angiography and Interventions
Icahn School of Medicine at Mount Sinai Hospital
Latest Radiography News
- Novel Breast Imaging System Proves As Effective As Mammography
- AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
- AI Could Boost Clinical Adoption of Chest DDR
- 3D Mammography Almost Halves Breast Cancer Incidence between Two Screening Tests
- AI Model Predicts 5-Year Breast Cancer Risk from Mammograms
- Deep Learning Framework Detects Fractures in X-Ray Images With 99% Accuracy
- Direct AI-Based Medical X-Ray Imaging System a Paradigm-Shift from Conventional DR and CT
- Chest X-Ray AI Solution Automatically Identifies, Categorizes and Highlights Suspicious Areas
- AI Diagnoses Wrist Fractures As Well As Radiologists
- Annual Mammography Beginning At 40 Cuts Breast Cancer Mortality By 42%
- 3D Human GPS Powered By Light Paves Way for Radiation-Free Minimally-Invasive Surgery
- Novel AI Technology to Revolutionize Cancer Detection in Dense Breasts
- AI Solution Provides Radiologists with 'Second Pair' Of Eyes to Detect Breast Cancers
- AI Helps General Radiologists Achieve Specialist-Level Performance in Interpreting Mammograms
- Novel Imaging Technique Could Transform Breast Cancer Detection
- Computer Program Combines AI and Heat-Imaging Technology for Early Breast Cancer Detection